Cheng Da Biotechnology
Human vaccines for rabies and Japanese encephalitis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
CNY266m | Post IPO Equity | ||
| Total Funding | 000k | ||
Liaoning Chengda Biotechnology Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and sale of human vaccines. Founded in 2002, the company is a subsidiary of the state-owned conglomerate Liaoning Chengda Co., Ltd. and is headquartered in Shenyang, China. The company listed on the Shanghai Stock Exchange's STAR Market on October 28, 2021.
The company's core products are a human rabies vaccine and an inactivated Japanese encephalitis vaccine. Its rabies vaccine was the first in China to use the Zagreb 2-1-1 injection method, and its Japanese encephalitis vaccine is the only domestically produced version of its kind available in China. The company's technology platform for large-scale vaccine preparation in bioreactors, developed through independent innovation in 2002, broke the long-term monopoly held by multinational corporations in China's high-end human rabies vaccine market. Chengda Biotechnology is a major global manufacturer and supplier of human rabies vaccines, with products sold across most of China and exported to over 30 countries.
The business operates through a model of research and development, manufacturing, and sales to a global market. Its client base includes approximately 2,000 district- and county-level disease control centers in China, as well as international markets in Asia, Africa, and other regions. The company operates R&D centers in Shenyang and Beijing and has production facilities in Shenyang and Benxi with an annual capacity of 10 million doses for both rabies and Japanese encephalitis vaccines. With over 20 products in its research pipeline, Chengda Biotechnology is developing vaccines for HPV, pneumococcus, and meningococcus.
Keywords: human vaccines, rabies vaccine, Japanese encephalitis vaccine, biopharmaceutical, vaccine manufacturing, drug discovery, biologics, immunization, infectious diseases, vaccine development, viral vaccine, bacterial vaccine, public health, pharmaceutical manufacturing, clinical trials, GMP certification, vaccine pipeline, biotech, Shenyang, Liaoning Chengda